Dymon Asia Capital Singapore PTE. LTD. Sells 18,400 Shares of Pfizer Inc. (NYSE:PFE)

Dymon Asia Capital Singapore PTE. LTD. cut its position in shares of Pfizer Inc. (NYSE:PFE) by 36.8% during the 4th quarter, HoldingsChannel reports. The firm owned 31,600 shares of the biopharmaceutical company’s stock after selling 18,400 shares during the period. Dymon Asia Capital Singapore PTE. LTD.’s holdings in Pfizer were worth $838,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC bought a new position in Pfizer during the 4th quarter valued at approximately $26,000. Rialto Wealth Management LLC bought a new stake in shares of Pfizer in the fourth quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC bought a new position in Pfizer during the fourth quarter valued at approximately $31,000. Finally, Curio Wealth LLC bought a new stake in Pfizer in the 4th quarter worth approximately $32,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PFE. UBS Group lowered their price target on Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a report on Tuesday. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. The Goldman Sachs Group restated a “neutral” rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday. Finally, Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.07.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by corporate insiders.

Pfizer Stock Performance

Pfizer stock opened at $21.57 on Friday. The company’s 50-day moving average price is $25.33 and its 200-day moving average price is $26.45. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market cap of $122.32 billion, a PE ratio of 15.30, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.10 earnings per share. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.